<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05790993</url>
  </required_header>
  <id_info>
    <org_study_id>BIOLI012021</org_study_id>
    <nct_id>NCT05790993</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the Bioli IOL Delivery System (BIOLI-D)</brief_title>
  <official_title>Clinical Evaluation of the Bioli IOL Delivery System (BIOLI-D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AST Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AST Products, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cataract surgery is one of the most frequent surgeries carried out in the world. After&#xD;
      cataract extraction an intraocular lens (IOL) is implanted in order to compensate for the&#xD;
      crystalline lens power and correct patient's vision. In order to allow cataract extraction&#xD;
      and IOL insertion, during the surgery a small incision is performed by the surgeon. This&#xD;
      incision is performed using surgical knives, and a smaller incisi√≥n is associated with less&#xD;
      postoperatory inflammation, faster corneal wound healing, and faster visual recovery. Several&#xD;
      studies reported the importance of smaller incisions to reduce the risk of surgically induced&#xD;
      astigmatism.&#xD;
&#xD;
      In order to implant the IOL through this small incision, the IOL must be preloaded in a&#xD;
      injector that allows introducing the IOL eficiently and consistently. The manual injector&#xD;
      BIOLI manufactured by AST Products (model D), CE approved, is designed specifically to allow&#xD;
      the IOL insertion safely, precisely, and controllably. Among the main characteristics of this&#xD;
      delivery system is its design to minimize the incision size widening while inserting the IOL.&#xD;
&#xD;
      The present retrospective study aims to provide more information with regards to the clinical&#xD;
      efficacy of the BIOLI-D delivery system for the implantation of the trifocal Asqelio&#xD;
      TFLIO130C IOL in patients submitted to cataract surgery. This will be assessed by analyzing&#xD;
      the change in incision size after IOL implantation and the incidence of adverse events during&#xD;
      and after the procedure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 20, 2022</start_date>
  <completion_date type="Actual">July 20, 2022</completion_date>
  <primary_completion_date type="Actual">July 20, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incision size after incision</measure>
    <time_frame>Immediately after clear incision is performed</time_frame>
    <description>Determined using a Capsulorhexis Incision Gauge Set, in mm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incision size before IOL implantation</measure>
    <time_frame>Immediately after phacoemulsification is complete</time_frame>
    <description>Determined using a Capsulorhexis Incision Gauge Set, in mm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incision size after IOL implantation</measure>
    <time_frame>Immediately after IOL implantation</time_frame>
    <description>Determined using a Capsulorhexis Incision Gauge Set, in mm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>During or after the surgical procedure</time_frame>
    <description>Incidence of adverse events related to the use of the device, coded according to the Medical Dictionary for Regulatory Activities, and analyzed per eye (ocular), and per subject (non ocular)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>Before surgery</time_frame>
    <description>Visual acuity in LogMAR units with best correction for distance, evaluated at a distance of 4m using ETDRS optotype</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Visual acuity in LogMAR units with best correction for distance, evaluated at a distance of 4m using ETDRS optotype</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Refractive error PreOp</measure>
    <time_frame>Before surgery</time_frame>
    <description>Manifest refraction before surgery in Diopters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Refractive error PostOp</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Manifest refraction after surgery in Diopters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure (IOP)</measure>
    <time_frame>Before surgery</time_frame>
    <description>Preoperative intraocular pressure measured in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cataract grading</measure>
    <time_frame>Before surgery</time_frame>
    <description>Cataract grading before surgery using the LOCS III grading system</description>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Cataract Senile</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with bilateral cataract submitted to cataract surgery by phacoemulsification and&#xD;
        implantation of Asqelio trifocal TFLIO130C IOL using the BIOLI-D delivery system&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 50 years or older submitted to cataract surgery and implanted with Asqelio&#xD;
             trifocal TFLIO130C IOL using the BIOLI-D delivery system.&#xD;
&#xD;
          -  Patients submitted to bilateral cataract surgery.&#xD;
&#xD;
          -  Transparent ocular media, other than the bilateral cataract.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Preoperatory corneal astigmatism greater than 0.75D&#xD;
&#xD;
          -  Corneal surgery or trauma prior to cataract surgery Irregular cornea&#xD;
&#xD;
          -  Choroidal hemorrhage&#xD;
&#xD;
          -  Microftalmos Severe corneal dystrophy&#xD;
&#xD;
          -  Uncontrolled or medically controlled glaucoma&#xD;
&#xD;
          -  Clinically significant macular changes&#xD;
&#xD;
          -  Concomitant ocular disease&#xD;
&#xD;
          -  Not age-related cataract&#xD;
&#xD;
          -  Severe optic nerve atrophy&#xD;
&#xD;
          -  Diabetic retinopathy&#xD;
&#xD;
          -  Proliferative diabetic retinopathy&#xD;
&#xD;
          -  Amblyopia&#xD;
&#xD;
          -  Extremelly shallow anterior chamber&#xD;
&#xD;
          -  Severe chronic uveitis&#xD;
&#xD;
          -  Rubella&#xD;
&#xD;
          -  Mature/dense cataract difficulting fundas assessment preoperatively&#xD;
&#xD;
          -  Prior retinal detachment&#xD;
&#xD;
          -  Concurrent participation in another investigation with medication or clinical devices&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>OftalVist Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>February 13, 2023</study_first_submitted>
  <study_first_submitted_qc>March 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2023</study_first_posted>
  <last_update_submitted>March 17, 2023</last_update_submitted>
  <last_update_submitted_qc>March 17, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

